Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
GEN
South San Francisco, California, United Statesgene.com ↗
- Ownership
- Public · GEN
- Employees
- ~13500
- Development stage
- Other
01
Overview
Genentech pioneered recombinant DNA technology with first-in-class products like synthetic human insulin. It has developed numerous blockbuster drugs such as trastuzumab (Herceptin), bevacizumab (Avastin), rituximab (Rituxan), and ocrelizumab (Ocrevus). The company continues to advance therapies across oncology, immunology, neuroscience, ophthalmology and rare diseases with a robust clinical pipeline at all stages.
- Therapeutic areas
- OncologyNeurology
- Modalities
- Monoclonal antibodySmall moleculeAntibody-drug conjugateProtein
- Industry
- Pharma
02
Partnerships
Novartis (co-development/commercialization e.g., Xolair)City of Hope Medical CenterEli Lilly & Co. (licensed Humulin from Genentech's technology)
03
Financials
- Market cap
- $18.2B
- Total revenue
- $5B
- Enterprise value
- $25.7B
Beyond the preview
Go deeper on GEN.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GEN.